Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ADVANZ PHARMA Corp

http://www.advanzpharma.com

Latest From ADVANZ PHARMA Corp

Deals Abound At Advanz

Advanz has acquired exclusive rights to register and commercialize a Phase III candidate from Dimerix in multiple territories, alongside agreements with Kyowa Kirin, Bayer and GP Pharm.

Deals Strategy

Alvotech Makes Multiple Moves As It Allies With Advanz For Five European Biosimilars

In a busy week for Alvotech, the firm has announced an expansion of its partnership with Advanz to cover five further European biosimilars, at the same time as revealing two new pipeline assets. Meanwhile, the company has also dropped three products from an existing European partnership with Stada and has also terminated a development deal with BiosanaPharma.

Deals Biosimilars

Asia Deal Watch: Aditum Bio Launches Vitalli To Develop Daewoong Immunology Candidate

In addition, deals involving Lupin/Medisol, Junshi/Dr. Reddy's, Zai Lab/MediLink, Kyowa Kirin/ADVANZ, Ipca/Unichem, Jiangsu Aidea/Kainos.

Deal Watch Deals

Concizumab, Elranatamab & Talquetamab Among New EU Filings At EMA

The European Medicines Agency has started reviewing a new batch of medicines for potential pan-EU marketing approval.

Europe Approvals
See All

Company Information

  • Industry
  • Pharmaceuticals
UsernamePublicRestriction

Register